Resveratrol inhibits osteoporosis in mice model

Abstract

Our study intends to assess whether resveratrol can ameliorate osteoporosis in mice. Ovariectomized (OVX) mice were established to measure SFRP1 level and SFRP1-siRNA was used to assess its effect on BMSCs osteogenesis. SFRP1 was significantly up-regulated in bone tissues and BMSCs of OVX mice with a gradual decrease during osteogenesis. However, it was not changed during BMSCs differentiation towards osteoclasts. SFRP1 knockdown significantly increased mineralization potentiality, elevated ALP activity and upregulated several osteoblast-specific genes. Moreover, bone loss was reduced in resveratrol-treated OVX mice, possibly through upregulating osteogenesis-associated genes and downregulating SFRP1. In conclusion, resveratrol ameliorates osteogenesis of BMSCs, implying that it might be utilized for treating PMOP.

The effects of resveratrol in animal models of primary osteoporosis: a systematic review and meta-analysis

“… Tb.N Analysis of 18 studies [ 19 , 25 – 27 , 33 , 35 – 38 , 40 , 41 ] showed that, compared with the control group, the Res group had markedly greater total bilirubin (Tb.N) ( n = 242; SMD, 1.68; 95% CI, 0.95 to 2.42; I 2 = 74%, P < 0.00001). Tb.Th Analysis of 18 studies [ 19 , 25 , 26 , 30 , 33 , 35 – 37 , 40 , 41 ] showed that, compared with that in the control group, the Tb.Th in the Res group was markedly greater ( n = 248; SMD, 1.73; 95% CI, 1.09 to 2.37; I 2 = 71%, P < 0.00001). Tb.Sp Analysis of 20 studies [ 19 , 25 – 27 , 30 , 33 , 35 – 38 , 40 , 41 ] showed that, compared with that in the control group, the Tb.Sp in the Res group was markedly lower ( n = 278; SMD, − 1.76; 95% CI, − 2.35 to − 1.16; I 2 = 70%, P < 0.00001).…”

“…Analysis of 18 studies [ 19 , 25 , 26 , 30 , 33 , 35 – 37 , 40 , 41 ] showed that, compared with that in the control group, the Tb.Th in the Res group was markedly greater ( n = 248; SMD, 1.73; 95% CI, 1.09 to 2.37; I 2 = 71%, P < 0.00001).…”

“… ALP Analysis of 16 studies [ 15 , 19 , 22 , 24 , 25 , 31 , 39 , 40 ] showed that, compared with that in the control group, ALP was markedly lower in the Res group ( n = 198; SMD, − 1.69; 95% CI, − 3.01 to − 0.37; I 2 = 87%; P < 0.05). bALP Analysis of 3 studies [ 21 , 36 , 37 ] showed that, compared with those in the control group, the bALP levels in the Res group were markedly greater ( n = 52; SMD, 4.11; 95% CI, − 0.77 to 8.99; I 2 = 95%, P > 0.05). OC Analysis of 10 studies [ 15 , 22 , 25 , 31 , 33 ] showed that, compared with that in the control group, the OC in the Res group was markedly lower ( n = 134; SMD, − 0.86; 95% CI, − 2.11 to 0.39; I 2 = 86%, P > 0.05).…”

“… CTX-1 Analysis of 9 studies [ 24 , 27 , 36 , 39 , 40 ] showed that, compared with the control group, the Res group had markedly lower CTX-1 levels ( n = 100; SMD, − 1.81; 95% CI, − 2.41 to − 1.21; I 2 = 37%, P < 0.00001). TRAP5b Analysis of 7 studies [ 22 , 31 , 36 , 37 , 40 ] showed that, compared with the control group, the Res group had markedly lower TRAP5b levels ( n = 100; SMD, − 2.78; 95% CI, − 4.44 to − 1.12; I 2 = 85%, P < 0.01). …”

“…Analysis of 3 studies [ 21 , 36 , 37 ] showed that, compared with those in the control group, the bALP levels in the Res group were markedly greater ( n = 52; SMD, 4.11; 95% CI, − 0.77 to 8.99; I 2 = 95%, P > 0.05).…”